Chimeric antigen receptor T cells therapy in solid tumors

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is an adoptive cell transfer (ACT) therapy that engineers T cells to recognize and destroy tumor cells.
• CARs provide T cells with enhanced tumor antigen recognition capabilities, independent of human leukocyte antigen (HLA) presentation, and can target a broader range of antigens than natural T cell receptors (TCRs).
• CAR-T cell structure includes an extracellular antibody-derived scFv for targeting, a hinge region, transmembrane spacer, and intracellular signaling domains, with varying generations distinguished by costimulatory domains.

Purpose of the Study:

• To review the advancements and limitations of CAR-T cell therapy in cancer treatment.
• To discuss strategies for overcoming challenges such as antigen escape, tumor microenvironment interactions, and CAR-T cell infiltration in solid tumors.
• To highlight the importance of managing CAR-T cell-related toxicities, including cytokine release syndrome (CRS) and on-target/off-tumor effects.

Main Methods:

• Review of existing literature on CAR-T cell therapy.
• Analysis of CAR-T cell design, including different generations and components.
• Examination of strategies to enhance CAR-T cell efficacy and safety, such as multiplexing and local administration.

Main Results:

• CAR-T therapy demonstrates significant potential but faces limitations including antigen escape and the complex tumor microenvironment.
• Multiplexing CAR-T cells and engineering them to modulate the tumor microenvironment are strategies to improve targeting and efficacy.
• Challenges in solid tumor treatment include CAR-T cell infiltration, addressed by local administration, and significant toxicities like CRS and on-target/off-tumor effects.

Conclusions:

• CAR-T cell therapy is a promising cancer immunotherapy, but overcoming limitations is crucial for wider adoption.
• Strategies to enhance CAR-T cell function and mitigate toxicity are essential for successful clinical translation.
• Further research and development in toxicity management are needed to enable broader implementation of CAR-T therapy beyond specialized centers.